









Markets
/
Stocks
/
nasdaq-anab
/

AnaptysBio Inc

ANAB

49.730USD

+1.830+3.82%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.37BMarket Cap

LossP/E TTM



AnaptysBio Inc

49.730

+1.830+3.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AnaptysBio Inc

Currency: USD Updated: 2026-02-06

Key Insights

AnaptysBio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 64.58.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AnaptysBio Inc's Score

Industry at a Glance

Industry Ranking

11 / 392

Overall Ranking

91 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

AnaptysBio Inc Highlights

StrengthsRisks

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 787.33% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 91.28M.

Undervalued

The company’s latest PE is -17.64, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 31.62M shares, increasing 0.03% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 13.87K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

64.583

Target Price

+34.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of AnaptysBio Inc is 7.78, ranking 78 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 76.32M, representing a year-over-year increase of 154.26%, while its net profit experienced a year-over-year increase of 146.00%.

Score

Industry at a Glance

Previous score

7.78

Change



Financials

5.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.71

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

AnaptysBio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of AnaptysBio Inc is 6.48, ranking 269 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -17.64, which is -87.77% below the recent high of -2.16 and -2.98% above the recent low of -18.16.

Score

Industry at a Glance

Previous score

6.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of AnaptysBio Inc is 8.62, ranking 91 out of 392 in the Biotechnology & Medical Research industry. The average price target is 62.50, with a high of 100.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

64.583

Target Price

+33.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

AnaptysBio Inc

ANAB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of AnaptysBio Inc is 9.29, ranking 22 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 53.67 and the support level at 44.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.94

Change

0.35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.061

Buy

RSI(14)

56.075

Neutral

STOCH(KDJ)(9,3,3)

61.531

Neutral

ATR(14)

2.794

High Vlolatility

CCI(14)

107.272

Buy

Williams %R

29.563

Buy

TRIX(12,20)

0.241

Sell

StochRSI(14)

45.199

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

49.552

Buy

MA10

48.732

Buy

MA20

47.958

Buy

MA50

46.482

Buy

MA100

39.202

Buy

MA200

30.818

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of AnaptysBio Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 161.07%, representing a quarter-over-quarter decrease of 3.10%. The largest institutional shareholder is Steven Cohen, holding a total of 2.27M shares, representing 8.18% of shares outstanding, with 1.50% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EcoR1 Capital, LLC

7.88M

Point72 Asset Management, L.P.

Star Investors

2.27M

-8.46%

The Vanguard Group, Inc.

Star Investors

1.47M

-3.95%

BlackRock Institutional Trust Company, N.A.

1.47M

-4.95%

Tang Capital Management, LLC

1.33M

+0.21%

Morgan Stanley & Co. LLC

1.32M

-19.36%

First Light Asset Management, LLC

990.16K

-53.60%

State Street Investment Management (US)

873.43K

+6.38%

Sanofi SA

821.92K

Millennium Management LLC

1.52M

+646.40%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AnaptysBio Inc is 5.15, ranking 54 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. AnaptysBio Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.